The invention set forth in the appended claims relates generally to tissue treatment systems and more particularly, but without limitation, to apparatuses with integrated fluid conductors and noise attenuation, and methods of manufacturing and using the same.
Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but it has proven particularly advantageous for treating wounds. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of a wound is important to the outcome. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as “negative-pressure therapy,” but is also known by other names, including “negative-pressure wound therapy,” “reduced-pressure therapy,” “vacuum therapy,” and “vacuum-assisted closure,” for example. Negative-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.
While the clinical benefits of negative-pressure therapy are widely known, the cost and complexity of negative-pressure therapy can be a limiting factor in its application, and the development and operation of negative-pressure systems, components, and processes continues to present significant challenges to manufacturers, healthcare providers, and patients.
New and useful systems, apparatuses, and methods related to tissue treatment are set forth in the appended claims. Illustrative embodiments are also provided to enable a person skilled in the art to make and use the claimed subject matter. For example, an apparatus is described herein that may include a panel with integrated fluid channels, wherein the panel and the fluid channel consist only of surfaces that can be manufactured with a straight-pull mold. A port may also be integrated into the panel and fluidly coupled to the fluid channel to facilitate coupling the fluid channel to pneumatic components in an assembly incorporating the panel. In more particular embodiments, a seal may be secured to the panel over the fluid channel to form an integrated fluid conductor. The seal is preferably an adhesive label that can also be used for product labeling.
Such an apparatus may be particularly advantageous for use in a control unit of a negative-pressure therapy system, wherein such an apparatus may employ several such integrated fluid conductors coupled to a pump and other pneumatic components. For example, some embodiments of a therapy apparatus may include a housing comprising a panel with integrated fluid conductors. Negative pressure produced by a pump can be delivered to a dressing via a first integrated fluid conductor. Moreover, in some embodiments, a second integrated fluid conductor may fluidly couple exhaust from the pump to an expansion chamber to attenuate exhaust noise from the pump. In some example embodiments, a baffle may be disposed in the expansion chamber to further attenuate noise. Additionally or alternatively, sound absorbing foam may also be disposed in the expansion chamber. Alternatively, other example embodiments may include an integrated fluid conductor configured to direct exhaust fluid along a serpentine path to attenuate noise.
In some embodiments, an apparatus may have a first housing and a second housing. A panel may be integral with or otherwise coupled to the second housing, and the panel may be configured with an integrated fluid channel disposed around a perimeter of the panel. Fasteners may be disposed through the panel within the perimeter defined by the integrated fluid conductor, and the fasteners may couple the second housing to the first housing. A seal may be secured to the panel over the fasteners and the integrated fluid channel. The integrated fluid conductor formed by the seal and the integrated fluid channel may fluidly couple a negative-pressure source to a negative-pressure outlet, such as a canister port. Removing the seal in such embodiments to gain access to the fasteners may break the pneumatic circuit between the negative-pressure source and the negative-pressure outlet, interfering with operation of the device. Accordingly, such embodiments may be advantageous for preventing tampering or other unauthorized disassembly.
Methods of manufacturing an apparatus are also described herein. Some example embodiments include molding a panel, wherein the mold forms a channel integral to the panel. The panel and the channel preferably consist of surfaces that can be molded with a straight-pull mold. A seal, such as an adhesive label, may be applied to the panel over the channel to form an integrated fluid conductor. In some embodiments, the mold further forms a port integral to the panel, wherein the port is fluidly coupled to the channel and configured to couple the channel to a pneumatic component. Preferably, the panel, the channel, and other features of the panel are substantially free of undercuts and overhangs.
Objectives, advantages, and a preferred mode of making and using the claimed subject matter may be understood best by reference to the accompanying drawings in conjunction with the following detailed description of illustrative embodiments.
The following description of example embodiments provides information that enables a person skilled in the art to make and use the subject matter set forth in the appended claims, but may omit certain details already well-known in the art. The following detailed description is, therefore, to be taken as illustrative and not limiting.
The example embodiments may also be described herein with reference to spatial relationships between various elements or to the spatial orientation of various elements depicted in the attached drawings. In general, such relationships or orientation assume a frame of reference consistent with or relative to a patient in a position to receive treatment. However, as should be recognized by those skilled in the art, this frame of reference is merely a descriptive expedient rather than a strict prescription.
In general, components of the therapy system 100 may be coupled directly or indirectly. For example, the negative-pressure source 104 may be directly coupled to the regulator 106 and indirectly coupled to the dressing 102 through the regulator 106. In some embodiments, components may be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Coupling may also include mechanical, thermal, electrical, or chemical coupling (such as a chemical bond) in some contexts.
Components may also be fluidly coupled to each other to provide a path for transferring fluids (i.e., liquid and/or gas) between the components. In some embodiments, for example, components may be fluidly coupled through a fluid conductor. A “fluid conductor,” as used herein, broadly refers to a tube, pipe, hose, conduit, or other structure with one or more lumina adapted to convey a fluid between two ends. A tube, for example, is typically an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary.
In operation, the tissue interface 110 may be placed within, over, on, or otherwise proximate to a tissue site. The cover 108 may be placed over the tissue interface 110 and sealed to tissue near the tissue site. For example, the cover 108 may be sealed to undamaged epidermis peripheral to a tissue site. Thus, the dressing 102 can provide a sealed therapeutic environment proximate to a tissue site, substantially isolated from the external environment, and the negative-pressure source 104 can reduce the pressure in the sealed therapeutic environment. Negative pressure applied across the tissue site through the tissue interface 110 in the sealed therapeutic environment can induce macrostrain and microstrain in the tissue site, as well as remove exudates and other fluids from the tissue site, which can be collected in container 112 and disposed of properly.
The fluid mechanics of using a negative-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to negative-pressure therapy are generally well-known to those skilled in the art, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” negative pressure, for example.
In general, exudates and other fluids flow toward lower pressure along a fluid path. Thus, in the context of a system for negative-pressure therapy, the term “downstream” typically implies something in a fluid path relatively closer to a negative-pressure source, and conversely, the term “upstream” implies something relatively further away from a negative-pressure source. Similarly, it may be convenient to describe certain features in terms of fluid “inlet” or “outlet” in such a frame of reference. This orientation is generally presumed for purposes of describing various features and components of negative-pressure therapy systems herein. However, the fluid path may also be reversed in some applications (such as by substituting a positive-pressure source for a negative-pressure source) and this descriptive convention should not be construed as a limiting convention.
The term “tissue site” in this context broadly refers to a wound or defect located on or within tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. A wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example. The term “tissue site” may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, negative pressure may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.
“Negative pressure” generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment provided by the dressing 102. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure.
A negative-pressure source, such as the negative-pressure source 104, may be a reservoir of air at a negative pressure, or may be a manual or electrically-powered device that can reduce the pressure in a sealed volume, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micro-pump, for example. A negative-pressure source may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate negative-pressure therapy. While the amount and nature of negative pressure applied to a tissue site may vary according to therapeutic requirements, the pressure is generally a low vacuum, also commonly referred to as a rough vacuum, between −5 mm Hg (−667 Pa) and −500 mm Hg (−66.7 kPa). Common therapeutic ranges are between −75 mm Hg (−9.9 kPa) and −300 mm Hg (−39.9 kPa).
The tissue interface 110 can be generally adapted to contact a tissue site. The tissue interface 110 may be partially or fully in contact with the tissue site. If the tissue site is a wound, for example, the tissue interface 110 may partially or completely fill the wound, or may be placed over the wound. The tissue interface 110 may take many forms, and may have many sizes, shapes, or thicknesses depending on a variety of factors, such as the type of treatment being implemented or the nature and size of a tissue site. For example, the size and shape of the tissue interface 110 may be adapted to the contours of deep and irregular shaped tissue sites.
In some embodiments, the tissue interface 110 may be a manifold. A “manifold” in this context generally includes any substance or structure providing a plurality of pathways adapted to collect or distribute fluid across a tissue site under negative pressure. For example, a manifold may be adapted to receive negative pressure from a source and distribute the negative pressure through multiple apertures across a tissue site, which may have the effect of collecting fluid from across a tissue site and drawing the fluid toward the source. In some embodiments, the fluid path may be reversed or a secondary fluid path may be provided to facilitate delivering fluid across a tissue site.
In some illustrative embodiments, the pathways of a manifold may be channels interconnected to improve distribution or collection of fluids across a tissue site. For example, cellular foam, open-cell foam, reticulated foam, porous tissue collections, and other porous material such as gauze or felted mat generally include pores, edges, and/or walls adapted to form interconnected fluid pathways. Liquids, gels, and other foams may also include or be cured to include apertures and flow channels. In some illustrative embodiments, a manifold may be a porous foam material having interconnected cells or pores adapted to uniformly (or quasi-uniformly) distribute negative pressure to a tissue site. The foam material may be either hydrophobic or hydrophilic. In one non-limiting example, a manifold may be an open-cell, reticulated polyurethane foam such as GranuFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex.
In an example in which the tissue interface 110 may be made from a hydrophilic material, the tissue interface 110 may also wick fluid away from a tissue site, while continuing to distribute negative pressure to the tissue site. The wicking properties of the tissue interface 110 may draw fluid away from a tissue site by capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
The tissue interface 110 may further promote granulation at a tissue site when pressure within the sealed therapeutic environment is reduced. For example, any or all of the surfaces of the tissue interface 110 may have an uneven, coarse, or jagged profile that can induce microstrains and stresses at a tissue site if negative pressure is applied through the tissue interface 110.
In some embodiments, the tissue interface 110 may be constructed from bioresorbable materials. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones. The tissue interface 110 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the tissue interface 110 to promote cell-growth. A scaffold is generally a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.
In some embodiments, the cover 108 may provide a bacterial barrier and protection from physical trauma. The cover 108 may also be constructed from a material that can reduce evaporative losses and provide a fluid barrier between two components or two environments, such as between a therapeutic environment and a local external environment. The cover 108 may be, for example, an elastomeric film or membrane that can be sealed around a tissue site to maintain a negative pressure at the tissue site for a given negative-pressure source. In some example embodiments, the cover 108 may be a polymer drape, such as a polyurethane film, that is permeable to water vapor but impermeable to liquid. Such drapes typically have a thickness in the range of 25-50 microns. For permeable materials, the permeability generally should be low enough that a desired negative pressure may be maintained.
An attachment device may be used to attach the cover 108 to an attachment surface, such as undamaged epidermis, a gasket, or another cover. The attachment device may take many forms. For example, an attachment device may be a medically-acceptable, pressure-sensitive adhesive that extends about a periphery, a portion, or an entire sealing member. In some embodiments, for example, some or all of the cover 108 may be coated with an acrylic adhesive having a coating weight between 25-65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, may be applied in some embodiments to improve the seal and reduce leaks. Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, or organogel.
The container 112 is representative of a container, canister, pouch, or other storage component, which can be used to manage exudates and other fluids withdrawn from a tissue site. In many environments, a rigid container may be preferred or required for collecting, storing, and disposing of fluids. In other environments, fluids may be properly disposed of without rigid container storage, and a re-usable container could reduce waste and costs associated with negative-pressure therapy.
The mounting foam 310 is preferably a low-density foam, which can positioned between the vacuum pump 302 and the housing 202. Illustrative examples of the mounting foam 310 include a melamine, polyester polyurethane, or impregnated polyether foam with a density approximately in the range of 10-100 kilograms per cubic meter. The mounting foam 310 may have an adhesive backing or may be pre-bonded to the first housing 312 and the second housing 314 in some embodiments to simplify assembly.
The seal 322 preferably comprises a material that is relatively pliable and impermeable to fluid. For example, the seal 322 may be manufactured from a non-porous polyester film, preferably having a thickness between 0.1 millimeter and 0.2 millimeter. The seal 322 also preferably comprises an adhesive or other suitable means for attaching the seal 322 to the second housing 314. For example, the seal 322 may include an acrylic adhesive applied to one side, preferably having a thickness of about 0.15 millimeters. In some embodiments, the seal 322 may also be an adhesive label or integrated with product labeling.
The expansion chamber 324 is preferably sealed to retain any condensation from humid air flowing through the expansion chamber in operation. For example, the mounting foam 310 may be compressed against the upper edges of the expansion chamber 324 to fluidly isolate the interior of the expansion chamber 324 from other components, particularly components that may be adversely affected by moisture.
One or more of the partitions 602 may also form at least part of the expansion chamber 324, as illustrated in the example embodiment of
One or more channel extensions may also be integrated into the panel 402. For example, channel extensions 608a-608c may be ridges or ribs that track the fluid channels 404a-404c in the panel 402, which can provide additional depth to the fluid channels. Moreover, at least one fluid port may also be coupled to the panel 402. For example, as shown in
In some embodiments, the second housing 314 may be manufactured with a molding process, such as injection molding. A mold preferably comprises two blocks machined to jointly provide a cavity having the shape and features of a part. To minimize the cost and efficiency of injection molding, a part preferably consists only of surfaces that allow a mold to be separated with a straight pull on the mold in at least one orientation. For example, an undercut on a part can prevent a straight pull on a mold, or may require a side pull that can increase the complexity and cost of manufacturing.
A part design may be visually inspected to identify undercuts or other features that may interfere with a straight pull mold in a particular orientation. Surface designs can also be analyzed by considering each line in a solid model, to determine if each line is continuous and intersects the part surface profile only at a single beginning and a single ending. An example of an automated geometric analysis of a solid model is described by Lukis et al. in U.S. Pat. No. 8,140,401, incorporated herein by reference. Surfaces can also be characterized by the angle between the surface and the direction of pull, referred to herein as the “parting angle.” In this context, the parting angle of a surface is equal to ninety degrees minus the angle between the direction of pull and a line that is normal to the surface and intersects the direction of pull. For example, a surface that is parallel to the direction of pull has a parting angle of zero degrees, and a surface that is perpendicular to the direction of pull and facing the direction of pull has a parting angle of ninety degrees. An undercut may also be characterized by a parting angle. For example, a surface that is perpendicular to the direction of pull but faces away from the direction of pull has a parting angle of negative ninety degrees (ninety degrees minus 180 degrees). Using this convention, an undercut has a parting angle less than zero degrees (a negative parting angle), and a part may be characterized as consisting only of straight-pull surfaces if all of the surfaces have a parting angle that is greater than or equal to zero degrees (a positive parting angle) in at least one orientation.
In some embodiments, the second housing 314 may consist entirely of straight-pull surfaces, which can be manufactured with a straight-pull mold in at least one orientation. For example, in some embodiments the direction of pull may be perpendicular to the panel 402, and the panel 402 (including the fluid channels 404a-404c) may consist of surfaces without overhangs or undercuts, which can be manufactured with a straight-pull mold opened perpendicular to the panel 402. Fluid ports, such as the fluid port 610, and channel extensions, such as the channel extensions 608a-608c, may also be designed without undercuts to facilitate straight-pull injection molding. Although the panel 402 is generally illustrated as integral to the second housing 314, the panel 402 may also be manufactured separately and fastened to the second housing 314 in some embodiments. The first housing 312 and other parts of the control unit 200 may also consist of straight-pull surfaces to reduce manufacturing complexity and cost.
In operation, the control unit 200 may be coupled to a canister, such as the container 112 of
Many negative-pressure therapy systems may use a reciprocating diaphragm or piston pump to generate negative pressure for therapy. For example, the vacuum pump 302 may be a reciprocating pump. In operation, this type of pump typically emits exhaust pulses, which can be a significant source of noise. Noise can be particularly problematic in smaller pumps that produce relatively high airflow rates, since smaller pumps generally rotate at a higher speed to produce higher flow rates. Excessive noise can interfere with patient compliance, particularly in public places or at night.
In some embodiments, a plenum or extended exhaust pathway, such as illustrated by the expansion chamber 324, the fluid channel 1412, or the expansion chamber 1514, can reduce pressure peaks of exhaust flow, reducing the sound level of an apparatus without significantly increase the size or cost of an apparatus. Baffles, sound-absorbing foam, or both may additionally or alternatively be used to reduce the sound level. For example, exhaust air from the positive-pressure port 1004 of the vacuum pump 302 may enter the expansion chamber 324 through the channel port 616. Within the expansion chamber 324, sound waves may be reflected and interfere with each other, which can significantly reduce the sound level, before leaving the expansion chamber 324 through an aperture in the panel 402. The mounting foam 310, which can seal the expansion chamber 324 in some embodiments, can also absorb sound waves to further reduce the sound level of an apparatus.
The systems, apparatuses, and methods described herein may provide significant advantages. For example, in some embodiments, the housing 202 can eliminate undercuts so that it can be molded with open-and-shut tooling, which can be significantly less expensive than other manufacturing processes. Fluid channels may also be integrated into an outer surface of the housing 202 to make desired fluid connections between components, which can significantly reduce the number of parts in a system. Reducing the number of parts can also reduce the cost and complexity of manufacturing. Moreover, reducing the use of ancillary tubing can also reduce the risk of connections blocked by twisted or bent tubes. To further reduce the amount of tubing required, some embodiments can combine integrated fluid channels with a custom fitting configured to make multiple fluid connections.
While shown in a few illustrative embodiments, a person having ordinary skill in the art will recognize that the systems, apparatuses, and methods described herein are susceptible to various changes and modifications. In particular, particular features may be emphasized in some example embodiments while being omitted in others, but a person of skill in the art will appreciate that features described in the context of one example embodiment may be readily applicable to other example embodiments. Moreover, descriptions of various alternatives using terms such as “or” do not require mutual exclusivity unless clearly required by the context, and the indefinite articles “a” or “an” do not limit the subject to a single instance unless clearly required by the context.
The appended claims set forth novel and inventive aspects of the subject matter described above, but the claims may also encompass additional subject matter not specifically recited in detail. For example, certain features, elements, or aspects may be omitted from the claims if not necessary to distinguish the novel and inventive features from what is already known to a person having ordinary skill in the art. Features, elements, and aspects described herein may also be combined or replaced by alternative features serving the same, equivalent, or similar purpose without departing from the scope of the invention defined by the appended claims.
This present invention is a divisional of U.S. patent application Ser. No. 14/849,321, entitled “THERAPY APPARATUS WITH INTEGRATED FLUID CONDUCTORS AND NOISE ATTENUATION,” filed Sep. 9, 2015, which claims the benefit, under 35 USC § 119(e), of U.S. Provisional Patent Application No. 62/048,638, entitled “THERAPY APPARATUS WITH INTEGRATED FLUID CONDUCTORS AND NOISE ATTENUATION,” filed Sep. 10, 2014, each of which is incorporated herein by reference for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3826254 | Mellor | Jul 1974 | A |
3888331 | Wang | Jun 1975 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4161264 | Malmgren et al. | Jul 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielsen | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4798580 | DeMeo et al. | Jan 1989 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4950235 | Slate et al. | Aug 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5464391 | DeVale | Nov 1995 | A |
5466229 | Elson et al. | Nov 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5746719 | Farra | May 1998 | A |
6071267 | Zamierowski | Jun 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6145160 | Buss et al. | Nov 2000 | A |
6241747 | Ruff | Jun 2001 | B1 |
6261065 | Nayak et al. | Jul 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
7563248 | Smisson, III et al. | Jul 2009 | B2 |
7846141 | Weston | Dec 2010 | B2 |
8062273 | Weston | Nov 2011 | B2 |
8216198 | Heagle et al. | Jul 2012 | B2 |
8251979 | Malhi | Aug 2012 | B2 |
8257327 | Blott et al. | Sep 2012 | B2 |
8398614 | Blott et al. | Mar 2013 | B2 |
8449509 | Weston | May 2013 | B2 |
8529548 | Blott et al. | Sep 2013 | B2 |
8535296 | Blott et al. | Sep 2013 | B2 |
8551060 | Schuessler et al. | Oct 2013 | B2 |
8568386 | Malhi | Oct 2013 | B2 |
8679081 | Heagle et al. | Mar 2014 | B2 |
8834451 | Blott et al. | Sep 2014 | B2 |
8926592 | Blott et al. | Jan 2015 | B2 |
9017302 | Vitaris et al. | Apr 2015 | B2 |
9198801 | Weston | Dec 2015 | B2 |
9211365 | Weston | Dec 2015 | B2 |
9289542 | Blott et al. | Mar 2016 | B2 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20020198503 | Risk et al. | Dec 2002 | A1 |
20020198504 | Risk et al. | Dec 2002 | A1 |
20070016152 | Karpowicz et al. | Jan 2007 | A1 |
20070107594 | Piccinini et al. | May 2007 | A1 |
20070135779 | Lalomia et al. | Jun 2007 | A1 |
20070167927 | Hunt et al. | Jul 2007 | A1 |
20070265586 | Joshi et al. | Nov 2007 | A1 |
20090030383 | Larsen et al. | Jan 2009 | A1 |
20090157016 | Adahan | Jun 2009 | A1 |
20090264837 | Adahan | Oct 2009 | A1 |
20090326488 | Budig et al. | Dec 2009 | A1 |
20100185165 | Middleton | Jul 2010 | A1 |
20100312202 | Henley et al. | Dec 2010 | A1 |
20110051136 | Milton et al. | Mar 2011 | A1 |
20110288512 | Locke et al. | Nov 2011 | A1 |
20120136325 | Allen et al. | May 2012 | A1 |
20130110058 | Adie et al. | May 2013 | A1 |
20140163487 | Tout et al. | Jun 2014 | A1 |
20140163491 | Schuessler et al. | Jun 2014 | A1 |
20140309619 | Agarwal et al. | Oct 2014 | A1 |
20150080788 | Blott et al. | Mar 2015 | A1 |
20150224237 | Reasoner et al. | Aug 2015 | A1 |
20160038658 | Chien et al. | Feb 2016 | A1 |
20160166781 | Sarangapani et al. | Jun 2016 | A1 |
20160250398 | Barr et al. | Sep 2016 | A1 |
20170274124 | Hartwell | Sep 2017 | A1 |
20170340784 | Hall et al. | Nov 2017 | A1 |
20180001000 | Herwig et al. | Jan 2018 | A1 |
20180111121 | Amshey | Apr 2018 | A1 |
Number | Date | Country |
---|---|---|
550575 | Mar 1986 | AU |
745271 | Mar 2002 | AU |
755496 | Dec 2002 | AU |
2005436 | Jun 1990 | CA |
1437488 | Aug 2003 | CN |
26 40 413 | Mar 1978 | DE |
43 06 478 | Sep 1994 | DE |
29 504 378 | Sep 1995 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0358302 | Mar 1990 | EP |
1018967 | Jul 2000 | EP |
692578 | Jun 1953 | GB |
2195255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 329 127 | Mar 1999 | GB |
2 333 965 | Aug 1999 | GB |
H07208144 | Aug 1995 | JP |
2006234600 | Sep 2006 | JP |
4129536 | Aug 2008 | JP |
71559 | Apr 2002 | SG |
8002182 | Oct 1980 | WO |
8704626 | Aug 1987 | WO |
90010424 | Sep 1990 | WO |
93009727 | May 1993 | WO |
9420041 | Sep 1994 | WO |
9605873 | Feb 1996 | WO |
9718007 | May 1997 | WO |
9818507 | May 1998 | WO |
9913793 | Mar 1999 | WO |
0118395 | Mar 2001 | WO |
2010075178 | Jul 2010 | WO |
2014082003 | May 2014 | WO |
Entry |
---|
Chinese First Office Action Corresponding to Application No. 2020104218275, dated Jun. 6, 2022. |
Louis C. Argenta, MD and Michael J. Morykwas, PHD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery; vol. 38, No. 6, Jun. 1997; pp. 563-576. |
Susan Mendez-Eatmen, RN; “When wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philidelphia, PA, USA. |
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
S.E. Greer, et al. “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995. |
PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999. |
PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999. |
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & dated Apr. 29, 1997. |
PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997. |
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
Yusupov. Yu.N., et al; “Active Wound Drainage”, Vestnki Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
Davydov, Yu.A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirugi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
Davydov, Yu.A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
Svedman, P. et al: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (certified translation). |
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
G. {hacek over (Z)}ivadinovi?, V. ?uki?, {hacek over (Z)}. Maksimovi?, ?. Radak, and P. Pes̆ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (certified translation). |
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (certified translation). |
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax, ”Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007. |
International Search Report and Written Opinion for corresponding PCT Application No. PCT/US2015/049240 dated Mar. 2, 2016. |
“By Design, Part design 107: Draft angles”, Injection Molding, Materials; Glenn Beall, Jan. 31, 2000 (Year: 2000). |
Chinese First Office Action for Corresponding Application No. 2015800514313, dated Dec. 18, 2018. |
Japanese Notice of Rejection corresponding to Application No. 2017-513071, dated Aug. 13, 2019. |
Extended European Search Report for Corresponding Application No. 19193338.1, dated Mar. 11, 2020. |
Number | Date | Country | |
---|---|---|---|
20200016302 A1 | Jan 2020 | US |
Number | Date | Country | |
---|---|---|---|
62048638 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14849321 | Sep 2015 | US |
Child | 16584523 | US |